Omar Infante is in some pain and is taking Toradol to treat it

29 Comments

Andy McCullough of the K.C. Star has a story on Omar Infante, who hit a big homer on Wednesday night. He’s doing what he’s doing through a lot of shoulder pain, however, which has sapped his effectiveness for a couple of months. But he’s taking some serious painkillers now which are helping:

“I feel better, because I’m taking strong pills,” Infante said. “That’s helped me a lot. I feel it a little bit in B.P., and I still feel sore in the front of my shoulder. But yesterday I felt more comfortable.”

Specifically, he’s taking Toradol, which is a pretty controversial drug. Many teams have banned it and it’s illegal in some other countries as well. It can cause some serious side effects, including internal bleeding. As Gordon Edes of ESPN Boston wrote in early 2013, Clay Buchholz believes it’s what led to him contracting esophagitis which landed him in the ICU a couple of years ago.

But it is used because, in some cases, teams and players feel they have to use it in order to get through the grind of the 162+ game season and get players in the position to play. In this way it’s much like what every player who has ever used HGH and other banned PEDs have said about why they used them. But that’s different. Because . . . well, it’s different. Trust us on this.

 

Report: Mets sign Brad Brach to one-year, $850,000 contract

Bryan Woolston/Getty Images
Leave a comment

The Athletic’s Ken Rosenthal reports that the Mets and free agent reliever Brad Brach have agreed on a one-year deal worth $850,000. The contract includes a player option for the 2021 season with a base salary of $1.25 million and additional performance incentives.

Brach, 33, signed as a free agent with the Cubs this past February. After posting an ugly 6.13 ERA over 39 2/3 innings, the Cubs released him in early August. The Mets picked him up shortly thereafter. Brach’s performance improved, limiting opposing hitters to six runs on 15 hits and three walks with 15 strikeouts in 14 2/3 innings through the end of the season.

While Brach will add some much-needed depth to the Mets’ bullpen, his walk rate has been going in the wrong direction for the last three seasons. It went from eight percent in 2016 to 9.5, 9.7, and 12.8 percent from 2017-19. Needless to say the Mets are hoping that trend starts heading in the other direction next season.